Mangalam Drugs and Organics Ltd updates on development of API Favipiravir

Mangalam Drugs and Organics Limited (the Company) is engaged in the business of manufacturing of various Active Pharmaceutical Ingredient (APIs).

The Company is constantly committed to perform healthy R&D as a result of which the Company have successfully developed the API Favipiravir which is being advised for the treatment of COVID - 19.

Once the Favipiravir API is approved by Food and Drug Administration (FDA) and the Government of India as a treatment of COVID-19, the Company will start production of the same and offer commercially in the market.

Shares of MANGALAM DRUGS & ORGANICS LTD. was last trading in BSE at Rs.63.65 as compared to the previous close of Rs. 64.2. The total number of shares traded during the day was 21025 in over 196 trades.

The stock hit an intraday high of Rs. 67.4 and intraday low of 61. The net turnover during the day was Rs. 1334613.

Source : Equity Bulls

Keywords